NCT05958004Completed
The Application Value of Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA Grey Area Prostate Cancer
Application Value of Biopsy Free Technique for Prostate Specific Antigen Grey Area Prostate Cancer Based on 18F-Prostate Specific Membrane Antigen-1007 Positron Emission Tomography/Computerized Tomography
Source: ClinicalTrials.gov · Last updated 17 Jul 2024
Brief summary (registry, in English)
The goal of this observational study is to establish an evaluation system for accurate identification of prostate cancer and clinical significant prostate cancer in patients in the PSA gray zone. The main questions it aims to answer are: proportion of men who could have avoided biopsy with positive PSMA-PET and no clinically significant cancer detected on biopsy. Participants will: 1. undergo PSMA PET/CT and multiparametric MRI; and 2. undergo prostate biopsy Researchers will compare the diagnostic performance of PSMA PET/CT and multiparametric MRI for prostate cancer and clinical significant prostate cancer to see if there are differences.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 92 (actual)
- First submitted
- 6 Jul 2023
- Start date
- 15 Jun 2023
- Primary completion date
- 30 Mar 2024
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Diseases
- Prostate cancer
- NCT number
- NCT05958004
What you commit to
- Study type: Observational
- Participants enrolled: 92
- From 15 Jun 2023 to the primary completion date, 30 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Coexisting with other malignancies
Who the study is looking for
- PSA (4-10 ng/mL)
- MRI and PSMA PET/CT were not contraindicated
- Did not receive prostate-related treatment
- There are no contraindications to biopsy
Age in the registry: 45 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Affiliated Hospital of Xi'an Jiaotong University Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.